$10.44
-6.8%Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Chief Business Officer
Chief Executive Officer, President & Director
Compensation
$854,402
Chief Operating Officer, Treasurer, Secretary & Principal Financial Officer
Compensation
$583,846
Senior Vice President of Clinical Development
Senior Vice President of Finance & Chief Accounting Officer
Senior Vice President of Program Management
Vice President & Head of Regulatory Affairs
During the last 12 months, insiders have purchased $1.14M and sold $1.85M worth of CLYM shares, resulting in $713K of net selling activity.
0
0.00
0
0.00
+0
+$0
321.7K
779.62K
150.0K
879.38K
-100K
-$100K
0
0.00
0
0.00
+0
+$0
280.0K
361.20K
621.9K
974.69K
-613K
-$613K
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$831K
Levin Andrew David
Director
$52K
Thomas Stephen Basil
Director
$52K
Williams Douglas E
Director
$52K
Dunn Judith
Director
$52K
Wilson Perrin Megan
Officer: Chief Business Officer
$948K
Thomas Stephen Basil
Director
$879K
Brennan Aoife
Director, Officer: President And Ceo
$25K
Pimblett Emily
Officer: Svp, Finance & Cao
$2K
Slightly bearish with $713K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
5 insider buyers vs. 4 sellers. More insiders buying than selling indicates positive sentiment.
CLYM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 05, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 04, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | April 06, 2023 | May 18, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 08, 2022 | May 19, 2022 | 2022 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.